Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)

NCT04849364 is registered in ClinicalTrials.gov with Bryan Schneider, MD as lead sponsor.

NCT NCT04849364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04849364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)
Lead sponsor
Bryan Schneider, MD
Phase
Phase 2
Overall status
Terminated
Start date
August 24, 2021
Completion date
December 2, 2024
Enrollment
52 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, triple negative breast cancer